Imipenem + cilastatin

Generic Medicine Info
Hypersensitivity to imipenem, cilastatin, or to any other carbapenems; severe hypersensitivity to other β-lactam antibiotics (e.g. penicillins or cephalosporins).
Special Precautions
CNS disorders (e.g. history of seizures, brain lesions). Renal impairment. Children. Pregnancy and lactation. Not recommended in children <30 kg with renal impairment or children with CNS infections. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor haematologic, renal, and hepatic function tests (periodically during prolonged therapy). Assess for signs of anaphylaxis during 1st dose.
Adverse Reactions
Significant: CNS adverse reactions (e.g. myoclonic activity, seizures, confusional states). Blood and lymphatic system disorders: Eosinophilia, neutropenia. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, staining of the teeth and/or tongue, taste perversion. General disorders and administration site conditions: Phlebitis/thrombophlebitis, pain, erythema, or induration at the injection site; fever. Investigations: Increased serum transaminases, serum alkaline phosphatase, serum bilirubin; decreased platelet count. Nervous system disorders: Dizziness, somnolence. Renal and urinary disorders: Proteinuria, oliguria/anuria. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria. Vascular disorders: Hypotension.
Potentially Fatal: Anaphylactic or hypersensitivity reactions; Clostridium difficile-associated diarrhoea (CDAD), pseudomembranous colitis (prolonged use). Rarely, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug Interactions
May induce generalised seizures with ganciclovir. Increased plasma concentration and half-life with probenecid. May increase anticoagulant effect of warfarin. Imipenem: May decrease serum concentrations and therapeutic efficacy of valproic acid.
CIMS Class
Other Beta-Lactams
Disclaimer: This information is independently developed by CIMS based on imipenem + cilastatin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in